Global Viscosupplementation for Knee Osteoarthritis Market Size By Type (Single Injection, Three Injection), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Viscosupplementation for Knee Osteoarthritis Market was valued at USD 3.1 billion in 2023 and is expected to reach USD 5.8 billion by 2031, growing at a CAGR of 8.2% during the forecast period from 2023 to 2031. Viscosupplementation is a minimally invasive treatment aimed at relieving pain and improving mobility in patients suffering from knee osteoarthritis (OA), especially those unresponsive to conventional therapy. The rising aging population, increasing prevalence of osteoarthritis, and growing preference for non-surgical interventions are major contributors to market expansion.

Drivers:

1. Growing Geriatric Population:

As the global elderly population rises, so does the incidence of knee osteoarthritis. This demographic shift is creating a larger patient pool requiring viscosupplementation as a preferred early intervention.

2. Minimally Invasive Nature of Viscosupplementation:

The procedure is minimally invasive, making it an attractive alternative to surgical treatments such as total knee replacement, especially for patients in early to moderate OA stages.

3. Increasing Awareness and Diagnosis:

With improving healthcare infrastructure and growing awareness among patients, early diagnosis of knee OA is becoming more common, boosting the demand for viscosupplementation treatments.

Restraints:

1. Limited Long-Term Efficacy:

While viscosupplementation provides short- to mid-term relief, concerns regarding its long-term efficacy limit its use in advanced OA stages.

2. Regulatory Hurdles and Reimbursement Challenges:

The classification of viscosupplementation agents and varying reimbursement policies in different countries pose a challenge to broader adoption.

Opportunity:

1. Expansion into Emerging Economies:

Rapid urbanization, a growing middle class, and improvements in healthcare access are opening new markets in Asia-Pacific, Latin America, and parts of Africa.

2. Advancements in HA Formulations:

Ongoing R&D is focused on developing next-generation hyaluronic acid (HA) formulations with enhanced viscoelastic properties and extended relief duration, offering differentiation opportunities for manufacturers.

Market by System Type Insights:

Based on the product type, the Single Injection Viscosupplementation segment accounted for the largest market share in 2023. Its popularity stems from convenience, reduced patient visits, and lower risk of infection compared to multi-injection treatments. However, the Three-Injection Viscosupplementation segment is also significant due to its established efficacy and wide clinical acceptance.

Market by End-use Insights:

In terms of end-use, Hospitals held the largest market share in 2023, followed by Ambulatory Surgical Centers (ASCs) and Orthopedic Clinics. Hospitals lead due to their broader patient base and availability of advanced imaging and diagnostic tools. However, ASCs are gaining traction due to lower procedural costs and shorter patient wait times.

Market by Regional Insights:

North America dominated the market in 2023 due to a high prevalence of knee OA, robust healthcare infrastructure, and supportive reimbursement policies. Europe followed closely, driven by early adoption of non-invasive orthopedic treatments. The Asia-Pacific region is anticipated to witness the highest CAGR during the forecast period, led by improving healthcare access, aging populations in countries like Japan and China, and growing awareness regarding osteoarthritis treatment.

Competitive Scenario:

Key players in the global viscosupplementation market include:

Sanofi S.A.

Zimmer Biomet Holdings, Inc.

Bioventus LLC

Ferring Pharmaceuticals

Anika Therapeutics, Inc.

Seikagaku Corporation

Smith & Nephew plc

Fidia Farmaceutici S.p.A.

These companies are focusing on strategic partnerships, new product development, and regulatory approvals to expand their product portfolios and geographic presence. For instance:

In 2024, Zimmer Biomet introduced a next-generation single-injection HA formulation with extended efficacy for up to 6 months.

Fidia Farmaceutici received CE approval for its HA injection aimed at moderate OA cases in 2023.

Bioventus expanded its distribution network in Southeast Asia to capitalize on emerging market demand in 2025.

Scope of Work – Global Viscosupplementation for Knee Osteoarthritis Market

Key Market Developments:

2023: Sanofi launched a digitally tracked HA injection platform allowing clinicians to monitor treatment response remotely.

2024: Seikagaku Corporation announced a partnership with a US-based orthopedic network to pilot its extended-release viscosupplement in clinical settings.

2025: Smith & Nephew expanded its viscosupplementation portfolio through the acquisition of a biotech startup specializing in next-gen HA molecules.

FAQs:

1) What is the current market size of the Global Viscosupplementation for Knee Osteoarthritis Market?

The market was valued at USD 3.1 billion in 2023.

2) What is the major growth driver of the Global Viscosupplementation for Knee Osteoarthritis Market?

The major growth driver is the rising geriatric population and growing preference for minimally invasive treatments.

3) Which is the largest region during the forecast period in the Global Viscosupplementation for Knee Osteoarthritis Market?

North America is the largest region, owing to its advanced healthcare infrastructure and favorable reimbursement policies.

4) Which segment accounted for the largest market share in the Global Viscosupplementation for Knee Osteoarthritis Market?

The Single Injection Viscosupplementation segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Viscosupplementation for Knee Osteoarthritis Market?

Key players include Sanofi, Zimmer Biomet, Bioventus, Anika Therapeutics, Ferring Pharmaceuticals, and Seikagaku Corporation.